Global private equity and venture capital news and research

Kala Pharmaceuticals scores $22.5m Series B

23 Apr 2014

dollar envelope moneyYsios Capital has led a $22.5m Series B round for Kala Pharmaceuticals, which is focused on developing ophthalmic products based on its mucus penetrating particle technology.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016